[1] Bos D, Arshi B, van den Bouwhuijsen Q J A, et al. Atherosclerotic Carotid Plaque Composition and Incident Stroke and Coronary Events
[J]. Journal of the American College of Cardiology, 2021, 77(11): 1426-1435.

[2] Maggi P, Ricci E D, Muccini C, et al. Subclinical atherosclerosis as detected by carotid ultrasound and associations with cardiac and HIV-specific risk factors; the Archi-Prevaleat project
[J]. HIV medicine, 2023, 24(5): 596-604.

[3] Gu Y, Miao C, Liu Y, et al. Correlation of carotid plaque and peripheral carotid adipose tissue characteristics with coronary computed tomography angiography-based fractional flow reserve
[J]. Journal of Cardiothoracic Surgery, 2025, 20(1): 261.

[4] Saba L, Cau R, Murgia A, et al. Carotid Plaque-RADS: A Novel Stroke Risk Classification System
[J]. JACC. Cardiovascular imaging, 2024, 17(1): 62-75.

[5] Mendieta G, Pocock S, Mass V, et al. Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years
[J]. Journal of the American College of Cardiology, 2023, 82(22): 2069-2083.

[6] Brunner G, Virani S S, Sun W, et al. Associations Between Carotid Artery Plaque Burden, Plaque Characteristics, and Cardiovascular Events: The ARIC Carotid Magnetic Resonance Imaging Study
[J]. JAMA cardiology, 2021, 6(1): 79-86.

[7] Hoogeveen R C, Ballantyne C M. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation
[J]. Clinical Chemistry, 2021, 67(1): 143-153.

[8] Vinci P, Di Girolamo F G, Panizon E, et al. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives
[J]. International Journal of Environmental Research and Public Health, 2023, 20(18): 6721.

[9] Oh M, Kim H, Shin E W, et al. Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation
[J]. Medicine, 2021, 100(10): e25114.

[10] Kadoglou N P, Khattab E, Velidakis N, et al. A new approach of statin therapy in carotid atherosclerosis: Targeting indices of plaque vulnerability on the top of lipid-lowering. A narrative review
[J]. Kardiologia Polska, 2022, 80(9): 880-890.

[11] Cui E, Kersche G, Grubic N, et al. Effect of pharmacologic anti-atherosclerotic therapy on carotid intraplaque neovascularization: A systematic review
[J]. Journal of Clinical Lipidology, 2023, 17(3): 315-326.

[12] Brinjikji W, Lehman V T, Kallmes D F, et al. The effects of statin therapy on carotid plaque composition and volume: A systematic review and meta-analysis
[J]. Journal of Neuroradiology = Journal De Neuroradiologie, 2017, 44(4): 234-240.

[13] Batty M, Bennett M R, Yu E. The Role of Oxidative Stress in Atherosclerosis
[J]. Cells, 2022, 11(23): 3843.

[14] Underberg J, Toth P P, Rodriguez F. LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals
[J]. Postgraduate Medicine, 2022, 134(8): 752-762.

[15] Vergallo R, Park S J, Stone G W, et al. Vulnerable or High-Risk Plaque: A JACC: Cardiovascular Imaging Position Statement
[J]. JACC. Cardiovascular imaging, 2025, 18(6): 709-740.

[16] Bashir B, Schofield J, Downie P, et al. Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape-focus on hypertriglyceridaemia
[J]. Frontiers in Cardiovascular Medicine, 2024, 11: 1389106.

[17] Henein M Y, Vancheri S, Longo G, et al. The Role of Inflammation in Cardiovascular Disease
[J]. International Journal of Molecular Sciences, 2022, 23(21): 12906.

[18] Ridker P M, Bhatt D L, Pradhan A D, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials
[J]. Lancet (London, England), 2023, 401(10384): 1293-1301.

[19] Gomez-Delgado F, Raya-Cruz M, Katsiki N, et al. Residual cardiovascular risk: When should we treat it?
[J]. European Journal of Internal Medicine, 2024, 120: 17-24.

[20] Ibanez B, Fernández-Ortiz A, Fernández-Friera L, et al. Progression of Early Subclinical Atherosclerosis (PESA) Study: JACC Focus Seminar 7/8
[J]. Journal of the American College of Cardiology, 2021, 78(2): 156-179.

[21] Nurmohamed N S, van Rosendael A R, Danad I, et al. Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography
[J]. European Heart Journal, 2024, 45(20): 1783-1800.

[22] Sillesen H, Sartori S, Sandholt B, et al. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans
[J]. European Heart Journal. Cardiovascular Imaging, 2018, 19(9): 1042-1050.

[23] van Rosendael S E, van den Hoogen I J, Lin F Y, et al. Clinical and Coronary Plaque Predictors of Atherosclerotic Nonresponse to Statin Therapy
[J]. JACC. Cardiovascular imaging, 2023, 16(4): 495-504.

[24] Gallone G, Bellettini M, Gatti M, et al. Coronary Plaque Characteristics Associated With Major Adverse Cardiovascular Events in Atherosclerotic Patients and Lesions: A Systematic Review and Meta-Analysis
[J]. JACC. Cardiovascular imaging, 2023, 16(12): 1584-1604.

[25] Eroshchenko N, Danilova E, Lomonosova A, et al. Plasma Fatty Acid Profiling and Mathematical Estimation of the Omega-3 Index: Toward Diagnostic Tools in Atherosclerosis and Statin Therapy Monitoring
[J]. Biomedicines, 2025, 13(6): 1383.

[26] Lieb W, Enserro D M, Larson M G, et al. Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community
[J]. Open Heart, 2018, 5(1): e000722.

[27] Pintó X, Fanlo M, Esteve V, et al. Remnant cholesterol, vascular risk, and prevention of atherosclerosis
[J]. Clinica E Investigacion En Arteriosclerosis: Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis, 2023, 35(4): 206-217.

[28] Chamaria S, Ueyama H, Yasumura K, et al. Coronary plaque vulnerability in statin-treated patients with elevated LDL-C and hs-CRP: optical coherence tomography study
[J]. The International Journal of Cardiovascular Imaging, 2022, 38(5): 1157-1167.

[29] Sarraju A, Nissen S E. Atherosclerotic plaque stabilization and regression: a review of clinical evidence
[J]. Nature Reviews. Cardiology, 2024, 21(7): 487-497.

[30] Wong N D, Zhao Y, Quek R G W, et al. Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis
[J]. Journal of Clinical Lipidology, 2017, 11(5): 1223-1233.